Video

Prof Ahmed Elzawawy

Brainstorming notes on oncology and AI

27 April 2026
LOAd703 combination therapy shows immune activation and promising responses in pancreatic cancer

Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer

24 April 2026
VCN-01 plus chemotherapy shows promising survival benefit in metastatic pancreatic cancer

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer

24 April 2026
ctDNA Predicts Early Treatment Response in HPV-Associated Anal Cancer

ctDNA predicts early treatment response in HPV-associated anal cancer

23 April 2026
Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer

23 April 2026
Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer

23 April 2026
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

23 April 2026
rana mckay

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

23 April 2026
T-cell engagers potential in SCLC treatment

The potential of T-cell engagers in SCLC treatment

23 April 2026
Available data and clinical trials in NSCLC and mesothelioma

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma

16 April 2026
Cemiplimab shows durable 6-Year survival benefit in PD-L1 high advanced NSCLC

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

16 April 2026
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

15 April 2026
Back to Top